AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large
Daiichi Sankyo made clear its ambition to transform into a global oncology leader when it wooed Ken Takeshita from Kite Pharma to become its R&D chief. Now, the Japanese pharma is throwing in the budget to back it up.
Takeshita will have $13.6 billion ($1.5 trillion yen) at his disposal over the next five years to steer new cancer treatments to blockbuster status. Chief among them will be a trio of antibody-drug conjugates, with the centerpiece being the AstraZeneca-partnered Enhertu, which has racked up $200 million in US sales in its first year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 106,500+ biopharma pros reading Endpoints daily — and it's free.